CD69 是肠道炎症的关键调节因子：IBD 治疗的新靶标分子？

U1019, Team 7, Institut National de la Santé et de la Recherche Médicale (INSERM), 1 rue du Professeur Calmette, 59019 Lille, France ; Center for Infection and Immunity of Lille, Institut Pasteur de Lille, 1 rue du Professeur Calmette, 59019 Lille, France.

Department of Visceral Surgery and Medicine, Inselspital, Freiburgstraße, 3010 Bern, Switzerland.

J Immunol Res. 2015;2015:497056. doi: 10.1155/2015/497056. Epub 2015 Feb 22.

CD69 has been identified as an early activation marker of lymphocytes. However, recent work has indicated that CD69 plays an essential role for the regulation of inflammatory processes. Particularly, CD69 is highly expressed by lymphocytes at mucosal sites being constantly exposed to the intestinal microflora (one of the nature's most complex and most densely populated microbial habitats) and food antigens, while only a small number of circulating leukocytes express this molecule. In this review we will discuss the role of CD69 in mucosal tissue and consider CD69 as a potential target for the development of novel treatments of intestinal inflammation.

CD69 被鉴定为淋巴细胞的早期激活标志物。然而，最近的研究表明 CD69 在炎症过程的调节中起着至关重要的作用。特别是，在黏膜部位经常暴露于肠道微生物群（自然界中最复杂和最密集的微生物栖息地之一）和食物抗原的淋巴细胞中高度表达 CD69，而只有少数循环白细胞表达这种分子。在这篇综述中，我们将讨论 CD69 在黏膜组织中的作用，并将 CD69 视为开发治疗肠道炎症的新疗法的潜在靶点。